[1]庞小坤,韩 梅,江心灿,等.当归补血汤治疗肿瘤化疗不良反应随机对照临床试验的Meta分析[J].医学信息,2019,32(02):69-74.[doi:10.3969/j.issn.1006-1959.2019.02.021]
　Pang Xiao-kun,Han Mei,Jiang Xin-can,et al.Meta-analysis of a Randomized Controlled Clinical Trial of Angelica Buxue Decoction in the Treatment of Adverse Reactions to Chemotherapy[J].Journal of Medical Information,2019,32(02):69-74.[doi:10.3969/j.issn.1006-1959.2019.02.021]
点击复制

当归补血汤治疗肿瘤化疗不良反应随机对照临床试验的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年02期
页码:
69-74
栏目:
论著
出版日期:
2019-01-15

文章信息/Info

Title:
Meta-analysis of a Randomized Controlled Clinical Trial of Angelica Buxue Decoction in the Treatment of Adverse Reactions to Chemotherapy
文章编号:
1006-1959（2019）02-0069-06
作者:
庞小坤1; 韩 梅2; 江心灿1; 赵宇昊1
1.首都医科大学中医药学院，北京 100069；2.北京中医药大学循证医学中心，北京 100029
Author(s):
Pang Xiao-kun1; Han Mei2; Jiang Xin-can1; Zhao Yu-hao1
1.School of Traditional Chinese Medicine,Capital Medical University,Beijing 100069,China;2.Center for Evidence-based Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100029,China
关键词:
当归补血汤; 肿瘤; 化疗; 不良反应
Keywords:
Angelica root; Blood tonic; DecoctionTumor; Chemotherapy; Adverse reactions
分类号:
R730.53
DOI:
10.3969/j.issn.1006-1959.2019.02.021
文献标志码:
A
摘要:
目的 系统评价目前当归补血汤治疗肿瘤化疗不良反应的疗效和安全性。方法 电子检索中国期刊全文数据库（CNKI）、万方数据库、中文科技期刊全文数据库（VIP）、中国生物医学文献服务系统（SinoMed）、美国国立医学图书馆（PubMed）、TheCochrane Library，截止2017年12月。应用Cochrane Risk of bias量表评价纳入研究的质量，釆用RevMan5.3软件进行Meta分析。结果 最终纳入14篇文献，包括1369例患者，Meta分析结局指标结果显示：白细胞水平升高[
Abstract:
Objective To systematically evaluate the efficacy and safety of angelica buxue decoction in the treatment of adverse reactions of tumor chemotherapy.Methods Electronic retrieval of CNKI, wanfang,VIP,SinoMed,PubMed,TheCochrane Library,as of December 2017.The Cochrane Risk of bias scale was used to evaluate the quality of included studies, and RevMan5.3 software was used for Meta analysis.Results A total of 14 references were included,including 1369 patients.Meta analysis of outcome indicators showed increased leukocyte levels [MD=1.25,95%CI (0.41,2.09), P＜0.00001], increased hemoglobin levels [MD=25.96,95% CI (15.59,36.34),P＜0.00001],and increased platelet levels [MD=26.82,95%CI (23.33, 30.31),P＜0.00001].IgG level increased [MD= 2.78,95%CI (1.99,3.56),P＜0.00001], IgA level increased [MD=0.30, 95%CI (-0.24,0.85),P＜ 0.00001], IgM level increased [MD=0.29, 95%CI (0.16,0.41), P＜0.00001], CD3+ level increased [MD=6.56, 95%CI (3.79, 9.34), P＜0.00001], CD4+ level increased [MD=5.77,95% CI (3.42,3.42), P＜0.00001],CD8+ levels [MD = 4.73,95% CI (6.62,2.83),P＜0.00001), bone marrow suppression Ⅲ and Ⅳ patients were reduced.Conclusion Angelica buxue decoction can increase the level of blood cells and serum immunoglobulin,stabilize the level of T lymphocytes and reduce bone marrow suppression in the treatment of adverse reactions to tumor chemotherapy.Angelica tonifying decoction has certain advantages and high safety in reducing adverse reactions of tumor chemotherapy.However,due to the high heterogeneity of the results, more high-quality randomized controlled clinical trials are needed.

参考文献/References:

[1]曾新颖,李镒冲,刘世炜, 等.1990—2015年中国四类慢性病早死概率与“健康中国2030”下降目标分析[J].中华预防医学杂志,2017,51(3):209-214.
[2]陈万青,孙可欣,郑荣寿,等.2014年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤,2018,27(1):1-14．
[3]潘睿.中国慢性病前瞻性研究队列恶性肿瘤发病与死亡分析[D].南京医科大学,2017.
[4]周向明,周昕,李毅民.当归补血汤的研究进展[J].世界中医药,2013,8(6):705-707．
[5]陈鹊汀,刘智勤,朱惠学,等.当归补血汤对乳腺癌术后化疗患者免疫功能的影响[J].时珍国医国药, 2009,20(5):1207-1208．
[6]李萍,吴华.当归补血汤加味治疗化疗后白细胞减少症66例[J].陕西中医,2008(8):951-952.
[7]闫晓轩.当归补血汤加味对大肠癌术后化疗减毒增效作用的临床研究[J].四川中医,2017,35(2):94- 96.
[8]范永田,李德川,徐新亚.当归补血汤联合化疗对中晚期大肠癌术后患者免疫功能的影响[J].中华中医药学刊,2013,31(12):2843-2844．
[9]蒋立峰,刘怀民.当归补血汤防治肿瘤化疗后骨髓抑制临床观察[J].中医学报,2013,28(4):475-477.
[10]李宝鸿,廉南.加味当归补血汤对肿瘤患者放化疗增效减毒作用的临床观察附:392例病例报告[J].成都中医药大学学报,2005,28(2):7-9.
[11]李燕.当归补血汤防治肿瘤化疗后骨髓抑制的临床探讨[J].中国医药科学,2013,3(18):110-111.
[12]廖大忠,李静,鲁光洪,等.加味当归补血汤治疗肿瘤相关性贫血72例临床观察[J].四川中医,2016,34 (1):81-83.
[13]穆大成.探究加味当归补血汤治疗肺鳞癌化疗后白细胞减少的效果[J]．内蒙古中医药，2017，36(14)：23.
[14]石惠燕,张凌燕,田义洲,等.加味当归补血汤对中晚期非小细胞肺癌化疗患者免疫功能及生活质量的影响[J].新中医,2017,49(3):106-108.
[15]孙雪飞,陈景寒,孟龙,等.当归补血汤Ⅰ号在非小细胞肺癌术前BAI化疗中的作用[J].山东大学学报(医学版),2006,44(3):280-282.
[16]王海波,陈鹊汀,李鹤飞,等.当归补血汤对中晚期肺癌化疗后免疫功能的影响[J].中医学报,2014，29(11):1553-1554.
[17]杨利芳.针对肿瘤患者应用当归补血汤对骨髓抑制的预防效果观察[J].世界最新医学信息文摘,2015, 15(14):99-100.
[18]张宇峰,付培亭,刘秀宝,等.当归补血汤联合重组人粒细胞刺激因子防治乳腺癌化疗后骨髓抑制效果观察[J].临床合理用药杂志,2015,8(28):8-10.
[19]王艳杰,康芯荣,张雨薇,等.当归补血汤抗肿瘤作用研究进展[J].中国医学装备,2017,14(8):165- 169.
[20]寿迪文,马伟斌.当归补血汤的不同配比对黄芪甲苷、阿魏酸及芒柄花素含量的影响[J].新中医,2016, 48(6):274-276.
[21]黄朝忠,刘智,苏颖.当归补血汤对肿瘤化疗增效减毒作用的研究进展[J].吉林中医药,2014,34(9)：962-964.
[22]严健,原永明,张舒,等.CD3+、CD4+、CD8+T淋巴细胞亚群在肿瘤患者外周血中检测的临床意义[J].检验医学,2013,28(10):901-903.
[23]王倩,侯改云.当归补血汤联合西药治疗对大肠癌术后细胞免疫功能及生存质量的影响[J].现代中西医结合杂志,2016,25(30):3339-3341.

相似文献/References:

[1]杨森果,毛大华,杨海松,等.E-cadherin与肿瘤侵袭、转移相关性研究进展[J].医学信息,2018,31(03):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
　YANG Sen-guo,MAO Da-hua,YANG Hai-song,et al.Research Progress of the Correlation between E-cadherin and Tumor Invasion and Metastasis[J].Journal of Medical Information,2018,31(02):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
[2]江立基,李先明.碳酸酐酶Ⅸ在肿瘤中的研究进展[J].医学信息,2018,31(03):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
　JIANG Li-ji,LI Xian-ming.Research Progress of Carbonic Anhydrase IX in Cancer[J].Journal of Medical Information,2018,31(02):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(02):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]白 雪,邓 琦.血液系统肿瘤的细胞治疗研究进展[J].医学信息,2018,31(10):41.[doi:10.3969/j.issn.1006-1959.2018.10.013]
　BAI Xue,DENG Qi.Advances in Cell Therapy for Blood System Tumor[J].Journal of Medical Information,2018,31(02):41.[doi:10.3969/j.issn.1006-1959.2018.10.013]
[5]李 轩,王子为,赵靖萱,等.肿瘤预后预测领域机器学习应用的文献计量与热点可视化分析[J].医学信息,2022,35(09):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
　LI Xuan,WANG Zi-wei,ZHAO Jing-xuan,et al.Visualization Analysis on Bibliometrics and Hot Spots of Machine Learning Applications in the Field of Tumor Prognosis Prediction[J].Journal of Medical Information,2022,35(02):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
[6]王 静,刘 梅,焦菊凤.知-信-行健康教育模式对PICC置管肿瘤 患者自我护理能力的影响[J].医学信息,2018,31(11):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
　WANG Jing,LIU Mei,JIAO Ju-feng.Effect of Knowledge-belief-behavioral Health Education Model on the Self-care Ability of Patients with Cancer in PICC Catheterization[J].Journal of Medical Information,2018,31(02):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
[7]史红娟,李群锋,赵 华,等.舒林酸抗肿瘤作用的研究进展[J].医学信息,2018,31(12):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
　SHI Hong-juan,LI Qun-feng,ZHAO Hua,et al.Advances in Research on Anti-tumor Effect of Sulindac[J].Journal of Medical Information,2018,31(02):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
[8]张 慧,胡广越,殷 红.菌群干预与免疫治疗的研究进展[J].医学信息,2022,35(11):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
　ZHAHG Hui,HU Guang-yue,YIN Hong.Research Progress in Microbial Intervention and Immunotherapy[J].Journal of Medical Information,2022,35(02):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
[9]郑文灿,法艳梅,吕亚青,等.苦参碱抗肿瘤机制的分子生物学研究进展[J].医学信息,2018,31(19):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]
　ZHENG Wen-can,FA Yan-mei,LV Ya-qing,et al.Advances in Molecular Biology of Matrine Antitumor Mechanism[J].Journal of Medical Information,2018,31(02):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]
[10]缪继东.盐酸吗啡缓释片联合低剂量阿米替林治疗中重度癌性骨痛的疗效观察[J].医学信息,2018,31(21):147.[doi:10.3969/j.issn.1006-1959.2018.21.042]
　MIAO Ji-dong.Effects of Morphine Hydrochloride Sustained-release Tablets Combined with Low Dose Amitriptyline in the Treatment of Moderate and Severe Cancer Bone Pain[J].Journal of Medical Information,2018,31(02):147.[doi:10.3969/j.issn.1006-1959.2018.21.042]

更新日期/Last Update: 2019-02-15